Trials / Completed
CompletedNCT00398216
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
A Phase IIb, Randomized, Parallel Group, Double-Blind, Double-Dummy, Multi-Center, Multi-National, Multi-Dose, Study of DU-176b Compared to Dalteparin in Patients Undergoing Elective Unilateral Total Hip Replacement
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 903 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to assess if DU176b is effective in prevention of blood clots following hip replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2007-06-01
- Completion
- 2007-06-01
- First posted
- 2006-11-10
- Last updated
- 2019-02-26
- Results posted
- 2015-02-25
Locations
29 sites across 7 countries: United States, Canada, Denmark, Hungary, Latvia, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00398216. Inclusion in this directory is not an endorsement.